NEW YORK (TheStreet) -- BioCryst Pharmaceuticals (BCRX - Get Report) rose Tuesday after the company announced its experimental drug for treating a rare immune disorder was effective in decreasing the disease's attacks in a mid-stage trial.
The trial compared the drug, BCX4161, to a placebo and tested it in patients with hereditary angioedema (HAE), a genetic disease that manifests with sudden attacks of swelling of the skin or the mucous membranes. The attacks can disfigure, cause pain and could even threaten patients' lives.
The results showed those treated with the drug had an average of 0.82 attacks per week, compared to 1.27 attacks per week for those given a placebo.
Must Read: Warren Buffett's 25 Favorite Stocks
The stock was up 8.83% to $9.80 at 11:17 a.m.